StreetInsider.com News Articles

Lexaria Bioscience CEO outlines 2025 progress and 2026 plans

Mon, 12 Jan 2026 09:10:38 -0500

Lexaria Bioscience Corp. (NASDAQ: LEXX) released its annual letter from CEO Richard Christopher detailing the company's 2025 achievements and outlining plans for 2026. The biotechnology company focuses on drug delivery platforms using its proprietary DehydraTECH technology.

During 2025, Lexaria conducted multiple human and animal studies examining its technology with three major GLP-1 drugs: semaglutide, tirzepatide, and liraglutide. The company completed its first Phase 1b registrational study in Australia and received 10 additional patents, expanding its portfolio to 56 patents worldwide.

The company raised $9.5 million through three equity offerings in 2025. Christopher noted the weighted average price of $7.5 million raised in

Lexaria Bioscience CEO outlines 2025 progress and 2026 plans

Mon, 12 Jan 2026 09:10:38 -0500

The company raised $9.5 million through three equity offerings in 2025. Christopher noted the weighted average price of $7.5 million raised in

Lexaria Bioscience CEO outlines 2025 progress and 2026 plans

Mon, 12 Jan 2026 09:10:38 -0500

The company raised $9.5 million through three equity offerings in 2025. Christopher noted the weighted average price of $7.5 million raised in

Lexaria Bioscience CEO outlines 2025 progress and 2026 plans

Mon, 12 Jan 2026 09:10:38 -0500

The company raised $9.5 million through three equity offerings in 2025. Christopher noted the weighted average price of $7.5 million raised in

Lexaria Releases Annual Letter from the CEO

Mon, 12 Jan 2026 09:10:00 -0500

KELOWNA, BC / ACCESS Newswire / January 12, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this Annual Letter from its Chief Executive Officer ("CEO") Richard Christopher as a strategic update to all stakeholders.

CEO Letter to Stakeholders

Dear Fellow Stakeholders,

I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year in the position.

I'm pleased to report that, in 2025, Lexaria made significant progress in further evidencing the potential to advance oral based drug delivery within

Lexaria Releases Annual Letter from the CEO

Mon, 12 Jan 2026 09:10:00 -0500

CEO Letter to Stakeholders

Dear Fellow Stakeholders,

I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year in the position.

I'm pleased to report that, in 2025, Lexaria made significant progress in further evidencing the potential to advance oral based drug delivery within

Lexaria Releases Annual Letter from the CEO

Mon, 12 Jan 2026 09:10:00 -0500

CEO Letter to Stakeholders

Dear Fellow Stakeholders,

I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year in the position.

I'm pleased to report that, in 2025, Lexaria made significant progress in further evidencing the potential to advance oral based drug delivery within

Lexaria Releases Annual Letter from the CEO

Mon, 12 Jan 2026 09:10:00 -0500

CEO Letter to Stakeholders

Dear Fellow Stakeholders,

I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year in the position.

I'm pleased to report that, in 2025, Lexaria made significant progress in further evidencing the potential to advance oral based drug delivery within

Lexaria reports additional Phase 1b study results for drug delivery platform

Tue, 30 Dec 2025 09:20:15 -0500

Lexaria Bioscience Corp. (NASDAQ: LEXX) released additional results from its Phase 1b clinical study examining its DehydraTECH drug delivery platform compared to Rybelsus in 126 overweight, obese, pre-diabetic and type-2 diabetic participants over 12 weeks.

The study found no statistically significant differences between DehydraTECH arms and Rybelsus control in secondary efficacy parameters including mean fasting glucose, cholesterol, and LDL cholesterol at week 16.

Body composition analysis showed the DehydraTECH-semaglutide arm had a lean mass reduction of 0.41 kg compared to 1.72 kg for Rybelsus, representing 37.96% of total weight loss versus 48.45% for the control arm. The DehydraTECH-CBD arm demonstrated blood pressure

Lexaria reports additional Phase 1b study results for drug delivery platform

Tue, 30 Dec 2025 09:20:15 -0500

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Tue, 30 Dec 2025 09:20:00 -0500

KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), recently completed in Australia, focusing on 4 DehydraTECH™ ("DHT") study arms relative to the Rybelsus® control study arm.

"We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria. "It adds to a growing

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Tue, 30 Dec 2025 09:20:00 -0500

"We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria. "It adds to a growing

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Tue, 30 Dec 2025 09:20:00 -0500

"We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria. "It adds to a growing

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Tue, 30 Dec 2025 09:20:00 -0500

"We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria. "It adds to a growing

Lexaria achieves primary endpoint in Phase 1b GLP-1 study

Tue, 23 Dec 2025 09:29:16 -0500

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that its Phase 1b study GLP-1-H24-4 successfully achieved its primary endpoint, demonstrating that DehydraTECH-semaglutide reduced overall side effects by 48% and gastrointestinal side effects by 55% compared to Rybelsus®.

The 12-week study conducted in Australia involved 126 overweight, obese, pre-diabetic and type-2 diabetic participants across five treatment arms. The primary endpoint assessed safety and tolerability based on treatment emergent adverse events.

DehydraTECH-semaglutide showed a 47.9% reduction in total adverse events compared to Rybelsus® and a statistically significant 54.9% reduction in gastrointestinal adverse events. All four DehydraTECH treatment arms demonstrated lower rates of overall and gastrointestinal adverse

Lexaria achieves primary endpoint in Phase 1b GLP-1 study

Tue, 23 Dec 2025 09:29:16 -0500

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Tue, 23 Dec 2025 09:29:00 -0500

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus^®
DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus^®
Recent financings create runway for prospective new 2026 development opportunities

KELOWNA, BC / ACCESS Newswire / December 23, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the " Study " or the " Lexaria Study "), recently completed in Australia, focusing on 4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Tue, 23 Dec 2025 09:29:00 -0500

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus^®
DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus^®
Recent financings create runway for prospective new 2026 development opportunities

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Tue, 23 Dec 2025 09:29:00 -0500

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus^®
DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus^®
Recent financings create runway for prospective new 2026 development opportunities

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Tue, 23 Dec 2025 09:29:00 -0500

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus^®
DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus^®
Recent financings create runway for prospective new 2026 development opportunities

Lexaria extends pharmaceutical partnership agreement through April 2026

Wed, 12 Nov 2025 09:11:03 -0500

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced the extension of its Material Transfer Agreement with an unnamed pharmaceutical company through April 30, 2026. The original agreement was signed on September 4, 2024.

The extension allows the pharmaceutical partner additional time to receive and review data from Lexaria's Australian clinical study. The agreement maintains a temporary exclusive license for the pharmaceutical company to evaluate Lexaria's DehydraTECH drug delivery technology in pre-clinical settings.

Initial pre-clinical studies examining pharmacokinetics in animals were completed earlier in 2025. The pharmaceutical partner has requested to review safety, pharmacokinetic and efficacy data from Lexaria's independent Australian human clinical study GLP-1-H24-4,

Lexaria extends pharmaceutical partnership agreement through April 2026

Wed, 12 Nov 2025 09:11:03 -0500

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Wed, 12 Nov 2025 09:10:00 -0500

KELOWNA, BC / ACCESS Newswire / November 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on September 4, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH^TM technology in a pre-clinical setting.

The original agreement has been extended through April 30, 2026, to accommodate time needed for PharmaCO's receipt and review of the full dataset from Lexaria's Australian study, at which time further information will be provided. This

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Wed, 12 Nov 2025 09:10:00 -0500

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Wed, 12 Nov 2025 09:10:00 -0500